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Nuclear receptor coactivator [peroxisome proliferator-activated
receptor-binding protein (PBP)/mediator subunit 1 (MED1)] is
a critical component of the mediator transcription complex. Dis-
ruption of this gene in the mouse results in embryonic lethality.
Using the PBP/MED1 liver conditional null (PBP/MED1DLiv)
mice, we reported that PBP/MED1 is essential for liver regener-
ation and the peroxisome proliferator-activated receptor a ligand
Wy-14,643-induced receptor-mediated hepatocarcinogenesis. We
now examined the role of PBP/MED1 in genotoxic chemical car-
cinogen diethylnitrosamine (DEN)-induced and phenobarbital-
promoted hepatocarcinogenesis. The carcinogenic process was
initiated by a single intraperitoneal injection of DEN at 14 days
of age and initiated cells were promoted with phenobarbital (PB)
(0.05%) in drinking water. PBP/MED1DLiv mice, killed at 1, 4
and 12 weeks, revealed a striking proliferative response of few
residual PBP/MED1-positive hepatocytes that escaped Cre-
mediated deletion of PBP/MED1 gene. No proliferative expansion
of PBP/MED1 null hepatocytes was noted in the PBP/MED1DLiv
mouse livers. Multiple hepatocellular carcinomas (HCCs) devel-
oped in the DEN-initiated PBP/MED1ﬂ/ﬂ and PBP/MED1DLiv
mice, 1 year after the PB promotion. Of interest is that all HCC
developing in PBP/MED1DLiv mice were PBP/MED1 positive.
None of the tumors was PBP/MED1 negative implying that hep-
atocytes deﬁcient in PBP/MED1 are not susceptible to neoplastic
conversion. HCC that developed in PBP/MED1DLiv mouse livers
were transplantable in athymic nude mice and these maintained
PBP/MED1ﬂ/ﬂ genotype. PBP/MED1ﬂ/ﬂ HCC cell line derived
from these tumors expressed PBP/MED1 and deletion of PBP/
MED1ﬂ/ﬂ allele by adeno-Cre injection into tumors caused necro-
sis of tumor cells. These results indicate that PBP/MED1 is essen-
tial for the development of HCC in the mouse.
Introduction
Nuclear receptors and many other regulated transcription factors con-
trol a surprisingly diverse array of genes capable of inﬂuencing many
biological processes (1,2). Transcriptional activation of genes is
a complex process, which involves the participation of many tran-
scription coactivators (3–5). These coactivators bind directly to tran-
scription factors and are involved in the remodeling of chromatin
structures and/or in bridging transcription factors with RNA polymer-
ase II and the general basal transcription machinery (4–7). Many of
these transcription coactivators along with other coregulatory mole-
cules bind singly or as preformed multisubunit protein complexes to
an activated transcription factor to enhance target gene transcription
(3–6). Since the cloning of the ﬁrst transcription coactivator steroid
receptor coactivator (7) and corepressors nuclear receptor corepressor
(8) and SMRT (9), over 300 coactivators/coregulators have been iden-
tiﬁed with new members still being added to this spectrum (4). This
diversity raises issues about the versatility and complexity of the
coregulatory molecules in orchestrating transcription and the need
to delineate speciﬁc functional roles of individual coregulators in
embryogenesis, development, differentiation and oncogenesis, as well
as energy and xenobiotic metabolism (4,10). Limited studies involv-
ing gene knockout mouse models show that some of the coactivators/
coregulators are essential for embryonic growth and survival, whereas
others are not critical for mouse embryogenesis (reviewed in ref. 10).
For example, the disruption of a coactivator gene such as peroxisome
proliferated-activated receptor (PPAR)-binding protein, which is also
known as thyroid hormone receptor-associated protein (TRAP) 220,
vitamin D3 receptor-interacting protein (DRIP) 205 or mediator sub-
unit 1 (MED1), referred to here as peroxisome proliferator-activated
receptor-binding protein (PBP)/MED1, results in embryonic lethality
in the mouse around gestational day 11.5 (11–15). Likewise, germ-line
deletion of coactivator peroxisome proliferator-activated receptor-
interacting protein (PRIP) (ASC-2/RAP250/TRBP/NRC/NCoA6)
gene and PRIP-interacting protein with methyltransferase domain
(PIMT/NCoA6IP) gene in the mouse also results in embryonic lethal-
ity (16–19). On the other hand, null mutation of coactivators steroid
receptor coactivator (20,21), SRC-2 (22), SRC-3 (23,24), PPAR
gamma coactivator 1 alpha (25) or coactivator associated arginine
methyl transferase 1 (26) results in viable phenotype with or without
overt functional changes.
To analyze the roles of PBP/MED1 and PRIP in adult tissues, we
generated mice for conditional gene disruption using the Cre-loxP
strategy (27,28). Using the albumin enhancer and promoter-driven
Cre recombinase transgene [Alb-Cre] (29) to mediate hepatocyte-
speciﬁc deletion of the PBP/MED1ﬂ/ﬂ allele, we demonstrated that
PBP/MED1 is essential for PPARa-regulated gene expression in liver
(27). Likewise, hepatocyte-speciﬁc deletion of the PBP/MED1ﬂ/ﬂ
allele resulted in near abrogation of the induction of constitutive
androstane receptor (CAR)-regulated genes in liver (30). In contrast,
deletion of PRIPﬂ/ﬂ allele in liver did not interfere with PPARa and
CAR signaling (28). The dependence of PPARa and CAR-regulated
gene transcription on coactivator PBP/MED1, but not on PRIP, attests
to the existence of coactivator selectivity in nuclear receptor function
at least in the liver (10,31). Furthermore, PBP/MED1 null hepatocytes
in PBP/MED1 liver conditional null (PBP/MED1DLiv) mice did not
develop hepatocellular carcinoma (HCC) when chronically exposed
to a PPARa ligand, indicating that PBP/MED1 is essential for this
receptor-mediated liver tumorigenesis (32). PPARa ligands, such as
ciproﬁbrate and Wy-14,643, are non-genotoxic hepatocarcinogens
(33) that differ from classical DNA-damaging mutagenic chemical
carcinogens (34). Typically, mutagenic chemicals and or their
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mutations and initiating the neoplastic change (34). Therefore, it
would be of importance to ascertain whether the PBP/MED1 null
hepatocytes function as targets for a potent genotoxic carcinogen
such as diethylnitrosamine (DEN) (35–38). Here, we used a DEN/
phenobarbital (PB) liver tumor-induction protocol to demonstrate that
PBP/MED1-deﬁcient mouse hepatocytes fail to develop liver tumors
in PBP/MED1DLiv mice. Initiation by DEN, followed by PB promo-
tion in PBP/MED1DLiv mice, resulted in a failure of PBP/MED1 null
hepatocytes to undergo proliferation. However, an occasional PBP/
MED1 expressing hepatocyte with PBP/MED1ﬂ/ﬂ genotype that es-
caped Alb-Cre-mediated deletion exhibited enormous proliferative
potential and such cells gave rise to liver tumors following DEN
initiation and PB promotion. PB exerts liver tumor promoting effects
by activating the nuclear receptor CAR (39) and since PBP/MED1
deﬁciency abrogates CAR function (30), it would appear that disrup-
tion of PBP/MED1 gene would have an impact on liver tumor de-
velopment. Furthermore, we established a transplantable HCC with
PBP/MED1ﬂ/ﬂ genotype in athymic nude mice and show that intra-
tumoral injection of Adeno-Cre-mediated deletion of PBP/MED1 al-
lele in tumor cells caused necrosis. These studies suggest PBP/MED1
is essential for development of HCC and required for the proliferative
expansion of liver cancers.
Materials and methods
Generation of PBP/MED1 conditional null mutation in liver (PBP/MED1DLiv)
and treatment with PB and DEN
The homozygous mutant mice lacking the PBP/MED1 in hepatocytes (PBP/
MED1DLiv) were generated and bred in our laboratory as described elsewhere
(27).MicecarryingPBP/MED1ﬂ/ﬂ (ﬂ,for ﬂankedbyLoxP)allelewerebredwith
a mouse containing albumin-Cre (AlbCre) transgene to generatePBP/MED1DLiv
mice (29). All the mice used for experiments were maintained in the C57BL/6
background. Micewere housed, under 12 h light–12 h dark cycle, in a pathogen-
free animal facility accredited by the Association for the Advancement and
Accreditation of Laboratory Animal Care International. They were maintained
on standard rodent chow (Teklad #7904; Harlan-Teklad, Indianapolis, IN) and
water adlibitum. Allthe experimentsinvolving PBP/MED1 livernulls and wild-
type mice were carried out using littermates. All animal procedures used in this
study were reviewed and preapproved by the Northwestern University Institu-
tional Animal Care and Use Committee. At 14 days postnatal age, the entire
mouse litter received a single intraperitoneal injection of the genotoxic tumor
initiator DEN (5 lg/g body weight; catalog no. N0756, Sigma, St Louis, MO;
dissolved in 0.9% saline) which induces hepatocyte DNA damage through
DNA adduct formation (37). Three days following injection of the tumor
initiator DEN, the mice were allowed free access to drinking water containing
tumor promoter PB (0.05%) until they were killed at speciﬁed intervals. Groups
of six to seven mice, containing both males and females, were used for the
experiments. Polymerase chain reaction (PCR) genotyping of mice was
performed using the following primers ﬂanking loxP site 1 in the ﬂoxed
PBP/MED1 allele; LoxPþ:5 #-TCCATCTGACCTGCTGGATGATAA-3’ and
LoxP :5 #- GGGTGTGACCCCATAATT-3#. Cre-speciﬁc primers used
included Cre-F: 5#-AGGTGTAGAGAAGGCACTCAGC-3’ and Cre-R: 5#-
CTAATCGCCATCTTCCAGCAGG-3#. PCR genotyping of tumor and non-
tumor areas in liver were performed using the following primers ﬂanking exons
8–10 in the ﬂoxed PBP/MED1 allele: PBPNA: 5#- GGTTATACATACCTT-
TCTGCTGT-3# and PBPNS: 5#- CCGTACAGTATCAGTCACCAT-3#.T h e s e
primers were also used for the genotyping of HCC cell lines derived from these
tumors. Microdissection was performed to excise 1   1 mm tumor and non-
tumorous tissue for DNA extraction. Groups of PBP/MED1ﬂ/ﬂ and PBP/
MED1DLiv mice were killed at 1, 4, 12 or 52 weeks after DEN injection. At
necropsy, terminal body weights, liver weights and liver morphology were eval-
uated. Livers were examined for the presence of liver tumors and sections of
liver, liver tumors and selected samples of lung were ﬁxed in 10% formalin or
4% paraformaldehyde and processed for light microscopic evaluation by three
authors (K.M., M.S.R. and J.K.R.) with liver pathology expertise.
Bromodeoxyuridine labeling, immunohistochemical staining and terminal
deoxynucleotidyl transferase-mediated dUTP nick-end labeling apoptosis
assay
To assess cell proliferation, bromodexoyuridine (BrdUrd) (0.5 mg/ml) was ad-
ministered in drinking water for 3 days and givena single intraperitoneal dose of
BrdUrd (100 mg/kg body wt) 2 h before killing (32). Liver and lung slices were
ﬁxed in 10% formalin or 4% paraformaldehyde, processed for embedding in
parafﬁn, sectioned and stained with either hematoxylin and eosin or processed
for the immunohistochemical localization of PBP/MED1 and BrdUrd or pro-
liferating cell nuclear antigen. The antibodies used were anti-PBP/MED1 (cat-
alog number sc-5334, Santa Cruz Biotechnology, Santa Cruz, CA), anti-BrdUrd
(BD Biosciences, San Jose, CA) and anti-PCNA (catalog number sc-25280,
Santa Cruz Biotechnology). To measure apoptosis in mouse liver isolated from
either untreated or DEN/PB-treated PBP/MED1ﬂ/ﬂ and PBP/MED1DLiv mice,
terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick
end labeling staining was performed on liver sections by using the in situ cell
death detection kit from Roche Applied Science (Indianapolis, IN) according to
the manufacturer’s recommendations. Histological analysis and image process-
ingwerecarriedoutusinga Leica DMREmicroscopeequippedwithSpotdigital
camera. Thevolume occupiedbylarge PBP/MED1positive hepatocytesin PBP/
MED1DLiv mice was estimated by using Scion Image software (http://scion-
image.software.informer.com/).
Tumor implantation in nude mice
Male athymic (nu/nu) mice, 5–6 weeks of age (Jackson Laboratory, Bar
Harbor, ME), were maintained in a pathogen-free environment, according to
an institutionally approved animal protocol, and given food and water ad
libitum. After 1 week’s acclimation, mice were anesthetized with nembutal
prior to tumor implantation. Liver tumors from PBP/MED1DLiv mice, har-
vested at the end of 1 year on DEN initiation and PB promotion, were chopped
into 1–2 mm cubes and one piece of tumor tissue was surgically implanted
subcutaneously on the back of nude mouse. Transplanted tumors were pro-
cessed for histopathological evaluation and for PBP/MED1 immunohisto-
chemical staining. To assess the role of PBP/MED1 in tumor cell survival,
we injected Adeno (Ad)-Cre-GFP viral particles (Vector Biolabs, Philadelphia,
PA) into the tumor transplanted in nude mice andthe tumor tissue examinedfor
histological alterations.
Generation of PBP/MED1ﬂ/ﬂ HCC cell lines (MED1ﬂ/ﬂHCC cell line)
To derive a HCC cell line from the PBP/MED1 expressing HCC serially trans-
planted in athymic nude mice, PBP/MED1ﬂ/ﬂ tumor tissue was dispersed with
collagenase or trypsin digestion into single cells or small cell clumps and these
were cultured in fresh Dulbecco’s modiﬁed Eagle’s medium (DMEM) con-
taining 10% fetal bovine serum. Two cell lines are established and designated
as PBP/MED1ﬂ/ﬂHCC1 and PBP/MED1ﬂ/ﬂHCC2 cell line.
Soft agar colony formation assay
Tumor cells (300) were suspended in a 1 ml mixture containing 0.35 (wt/vol)
agar DMEM supplemented with 10% fetal bovine serum. This mixture was
layeredona 1 mlbase of 0.7% (wt/vol) agar in DMEMwith10% fetalbovine
serum in a six-well plate and maintained in DMEM for 2 weeks. Colonies
were grown for 8 days and live pictures were taken on phase contrast micro-
scope. To check the affect of PBP/MED1 deletion in tumor cells, PBP/
MED1ﬂ/ﬂHCC cells were infected with 8   108 virus particle [Ad/Cre-
GFP or Ad/enhanced green ﬂuorescent protein (EGFP)] and 300 cells were
inoculated for 2 weeks and pictures were taken. Ad/Cre-GFP was purchased
from Vector Biolabs (catalog no. 1700) while Ad/EGFP was generated as
follows: coding sequence of EGFP was cloned into NotI and HindIII sites
of pShuttle-CMV expression vector (Quantum Biotechnologies, Quebec,
Canada). The shuttle vector and AdEASY vector (Quantum Biotechnolo-
gies) were linearized using PmeI and cotransformed into Escherichia coli
strain BJ5183 for the homologous recombination. Recombinant plasmid Ad/
EGFP was selected and Ad/EGFP virus was generated in HEK293A cells as
per manufacturer protocol.
Quantitative PCR analysis
Expression level of PBP/MED1 messenger RNA (mRNA) was analyzed
by real-time quantitative PCR (qPCR). Total RNA was extracted from
transplanted tumor tissues obtained from nude mice and liver samples from
PBP/MED1ﬂ/ﬂ and PBP/MED1DLiv mice using TRIzol reagent (Invitrogen,
Carlsbad, CA). Complementary DNA was prepared with 2 lg of total RNA
using SuperScriptTM III First-Strand Synthesis System for RT–PCR (Invitrogen)
and qPCR procedure was performed with SYBR Green Supermix (Applied
Biosystems, Foster City, CA) and the oligonucleotide for PBP/MED1 (5#-GAG-
ACTCCGCCCACTTACCG-3# and 5#-GGACACTTCAAACTGGAGG-3#),
insulin-like growth factor binding protein 1 (5#-TGCACCCGCCACGAGCA-
C-3# and 5#-GGGCCATCAGGTGGAAGCTGTC-3#), cyclin D (5#-G T G G -
TGGCTGCGATGCAAGG-3# and 5#-TGTTCCTGGCAGGCACGGAG-3#)
and cyclin B1 (5#-CCATGGCGCTCAGGGTCACTAG-3# and 5#-CCGGGCT-
TGGAAGCAGCAG-3#). Each sample was normalized on the basis of its
endogenous 18S ribosomal content and performed in triplicate.
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PBP/MED1 expressing hepatocytes exhibit growth advantage in PBP/
MED1DLiv mice during PB promotion
Previously, we demonstrated that chronic exposure to Wy-14,643,
a non-genotoxic hepatocarcinogen and a potent peroxisome prolifer-
ator, results in a rapid and sustained proliferation of PBP/MED1ﬂ/ﬂ
hepatocytes that escaped Cre-mediated gene deletion in PBP/
MED1DLiv mouse livers (27,32). PBP/MED1-positive hepatocytes
are easily discernible in Wy-14,643 treated PBP/MED1DLiv mouse
livers because of their large size, reﬂecting peroxisome proliferation
occurring in response to PPARa activation (27). All liver tumors that
developed in PBP/MED1 null livers expressed PBP/MED1 and no
tumor appeared to be derived from PBP/MED1-deﬁcient hepatocytes
(32). This led us to conclude that absence of PBP/MED1 abrogates the
response to PPARa ligand signaling required for liver tumorigenesis
with Wy-14,643 (32).
In the present study, it was decided to ascertain whether PBP/
MED1 null hepatocytes function as targets for tumor development
following DEN-initiation and PB promotion (35,37). DEN, in contrast
to PPARa ligand Wy-14,643, is a genotoxic chemical carcinogen and
the DEN-initiated hepatocytes are readily promotable when exposed
toliver tumorpromoter PB, anactivator of nuclear receptor CAR (38).
In the present study, following DEN initiation, PBP/MED1ﬂ/ﬂ and
PBP/MED1DLiv mice were given PB in drinking water and mice were
killed at selected intervals to examine changes in the liver. Liver
weight:body weight ratio was slightly lower in PBP/MED1DLiv mice
at 4 and 12 weeks on PB promotion and by 52 weeks, the ratios were
similar and the increase in ratio at this interval is due to liver tumor
burden (Figure 1). In mice given PB for 52 weeks without DEN
initiation, the liver weight:body weight ratio remained lower com-
pared with DEN-initiated animals (Figure 1). It should be noted that
1 year of PB treatment had similar effect of liver weight:body weight
ratio in normal and PBP/MED1 liver null mice and this is attributed to
PB accelerated expansion of the residual PBP/MED1 expressing hep-
atocytes in PBP/MED1DLiv mice. In PBP/MED1ﬂ/ﬂ mice, the histo-
logical appearance of liver was unremarkable at 0, 1 and 12 weeks of
PB promotion following DEN initiation (Figure 2A and C). All hep-
atocytes revealed PBP/MED1 nuclear staining (Figure 2B and D). In
PBP/MED1DLiv mice, nuclear staining of PBP/MED1 was not present
in hepatocytes at 0 day (Figure 2E and I), except for positive staining
in a rare hepatocyte that apparently escaped Cre-mediated gene de-
letion. By 1 week of PB promotion, large hepatocytes begin to emerge
in DEN-initiated PBP/MED1DLiv mouse livers (Figure 2F and J) and
they revealed PBP/MED1 nuclear staining implying PBPMED1ﬂ/ﬂ
genotype of these cells, in the background of PBP/MED1-deﬁcient
Fig. 2. Sequential histological changes in liver of PBP/MED1ﬂ/ﬂ and PBP/MED1DLiv mice. PBP/MED1ﬂ/ﬂ (A–D) and PBP/MED1DLiv (E–L) mice initiated with
DEN were promoted with PB in drinking water and killed after 0 (A, B, E and I), 1 (F and J), 12 (C, D, G and K) and 52 (H and L) weeks. Liver sections were
stained with hematoxylin and eosin (A, C and E–H) or processed for immunohistochemical localization of PBP/MED1 (B, D and I–L). In PBP/MED1ﬂ/ﬂ livers, all
hepatocyte nuclei are positive for PBP/MED1 (B and D; see boxed in D). In PBP/MED1DLiv mouse livers, large PBP/MED1-positive hepatocytes proliferate and
expand in number (see arrows in J and boxed area in H and L). These are distinct from PBP/MED1-deﬁcient small atrophic, relatively basophilic, PBP/MED1-
deﬁcient hepatocytes (boxed areas in G and K).
Fig. 1. Liver weight changes. Liver weight:body weight ratio at 0, 1, 4, 12
and 52 weeks in PBP/MED1ﬂ/ﬂ and PBP/MED1DLiv mice ( P , 0.05)
initiated with DEN and promoted with PB. The large increase in liver weight
at 52 weeks in DEN-initiated mice was due to the presence of liver tumors.
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320hepatocytes (Figure 2J). The PBP/MED1 expressing large hepato-
cytes in PBP/MED1DLiv livers increased in number and began to
dominate the liver phenotype in that they formed large expanding
colonies between 12 and 52 weeks of PB promotion (Figure 2G, H,
K and L). The volume occupied by large PBP/MED1-positive hepa-
tocytes in PBP/MED1DLiv mice was estimated by using Scion Image
software (Figure 3). The data on PBP/MED1 expressing large hepa-
tocytes obtained at 52 weeks (Figure 3) represents only the proportion
of these cells in non-neoplastic areas (see Figure 2H; Figure 4H).
These results indicate that few PBP/MED1 expressing hepatocytes
present in PBP/MED1DLiv mouse livers exhibit profound growth ad-
vantage in a milieu where the majority of hepatocytes do not express
this coactivator.
Hepatocellular proliferation was evaluated by BrdUrd incorpora-
tion and immunohistochemical staining (Figure 4). Signiﬁcant in-
crease in BrdUrd nuclear staining was observed at 1 week of PB
treatment in PBP/MED1ﬂ/ﬂ livers (Figure 4B) as compared with
PBP/MED1DLiv mouse livers (Figure 4F), which was similar to that
seen in 0 day controls (Figure 4A and E). In 12 week PB promoted
livers, the cell proliferation in PBP/MED1ﬂ/ﬂ livers was still higher
than in liver conditional nulls (Figure 4C). In PBP/MED1DLiv mouse
livers, BrdUrd nuclear staining was mostly conﬁned to large PBP/
MED1 expressing hepatocytes (Figure 4G) in comparison with ran-
dom labeling of hepatocytes throughout the liver lobule in ﬂoxed
controls (Figure 4C). At 52 weeks of PB promotion, hepatocellular
proliferation in non-tumorous areas in PBP/MED1DLiv mouse livers
was more than in non-tumorous areas in PBP/MED1ﬂ/ﬂ livers and this
increased BrdUrd nuclear staining liver conditional nulls was due to
proliferation of large PBP/MED1-positive hepatocytes and not in
smaller hepatocyte population (Figure 4D and H). We carried out
terminal deoxynucleotidyl transferase-mediated deoxyuridine tri-
phosphate nick end labeling staining of liver sections because hema-
toxylin and eosin stained sections of PBP/MED1DLiv mice showed
apoptotic alterations involving non-large hepatocyte areas represent-
ing PBP/MED1 null cells (not illustrated). It appeared that apoptosis
contributed to the progressive reduction in PBP/MED1-deﬁcient hep-
atocytes and this served as a stimulus for PBP-positive cells to pro-
liferate. On the other hand, proliferation of large PBP/MED1
expressing hepatocytes may exert compressive pressure on smaller
PBP/MED1-deleted hepatocytes forcing them to undergo cell death.
PBP/MED1 is necessary for DEN-induced liver carcinogenesis
At 52 weeks, the livers of both PBP/MED1ﬂ/ﬂ and PBP/MED1DLiv
mice that were initiated with DEN and promoted with PB revealed
multiple grossly visible tumors that were randomly distributed among
all liver lobes. Altered hepatic foci and hepatic adenomas were difﬁ-
cult to delineate due to proliferative expansion of hepatocytes, partic-
ularly in PBP/MED1DLiv mice. Accordingly, grossly and
histologically distinct HCC were evaluated and the HCC load ap-
peared similar in both groups (9.63 ± 2.69 in PBP/MED1ﬂ/ﬂ versus
9.13 ± 2.25 in PBP/MED1DLiv mice) (Figure 5A and B). Histologi-
cally, in both PBP/MED1ﬂ/ﬂ and PBP/MED1DLiv mice, a majority of
liver tumors was well to moderately differentiated HCC generally
with trabecular pattern (Figure 5C and E). We examined  30 tumors
from each group for the expression of PBP/MED1 (Figure 5D and F).
Interestingly, all liver tumors developed in PBP/MED1DLiv mice were
PBP/MED1 positive, whereas the surrounding non-tumor portions of
liver in these mice did not express this coactivator. Genotyping of
microdissected non-tumorous areas conﬁrmed PBP/MED1 gene de-
letion whereas tumors in these mice had intact gene. Large hepato-
cytes scattered in predominantly smaller PBP/MED1 gene deleted
hepatocytes in non-tumorous areas show PBP/MED1-positive nuclear
staining (Figures 2L, 4H and 5E and F). None of the tumors that
developed in PBP/MED1DLiv mice was PBP/MED1 negative,
Fig. 3. Increase in the volume of PBP/MED1-positive large hepatocytes in
DEN-initiated and PB promoted PBP/MED1DLiv mouse livers as analyzed by
Scion Image. The data obtained at 52 weeksrepresents onlynon-tumorareas.
Fig. 4. Hepatocellular proliferation in PBP/MED1ﬂ/ﬂ and PBP/MED1DLiv mouse livers following DEN initiation and PB promotion. Representative illustrations from
PBP/MED1ﬂ/ﬂ (A–D) and PBP/MED1DLiv (E–H) mouse livers. Hepatocellular proliferationwasassessedby BrdUrdlabeling at0(AandE),1 (Band F),12 (Cand G)
and 52 (D and H) weeks. BrdUrd incorporation was evaluated by immunohistochemistry. Many nuclei are labeled in PBP/MED1ﬂ/ﬂ mouse livers (B–D) at 1 (see
arrows and boxedareainB), 12(seearrows and boxedareas in C)and 52 (arrows inD) weekswhen comparedwith PBP/MED1DLiv mouse livers (F–H see arrows).In
PBP/MED1DLiv livers, BrdUrd labeling was observed only in PBP/MED-positive large hepatocytes (see arrows in F–H). At 52 weeks, the non-tumor areas in PBP/
MED1DLiv livers expanding populations of large hepatocytes are seen and PBP/MED1-negative hepatocytes are smaller (see boxed in H).
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change. As expected, all tumors in the PBP/MED1ﬂ/ﬂ mouse liver
expressedthis coactivator andall hepatocytes in non-tumorareas were
also PBP/MED1 positive (Figure 5D). We found occasional metasta-
sis in lungs of both PBP/MED1ﬂ/ﬂ and PBP/MED1DLiv mice bearing
HCC (Figure 6A–C). Immunohistochemical staining revealed the ex-
pression of PBP/MED1 in these metastatic tumor cells in the lung
(Figure 6D–F).
HCC implanted from PBP/MED1DLiv mouse into nude mouse reveal
PBP/MED1-positive phenotype
We transplanted small fragments of liver tumors obtained from PBP/
MED1DLiv mice following DEN initiation and PB promotion into the
anterior or posterior ﬂanks of athymic nude mice (Figure 7A and B).
By 4–5 weeks after initial transplantation, tumors appeared in the sites
of implantation and these grew to 10–40 mm3 by 50 days. These
tumors are being maintained by serial transplantation in nude mice
and the sixth passage is now in progress without apparent changes in
the histological pattern of tumors. Transplanted tumors revealed typ-
ical HCC appearance akin to that of HCC in DEN initiated and PB
promoted PBP/MED1DLiv mice (Figure 7B). These transplanted HCC
and PBP/MED1ﬂ/ﬂHCC1 and PBP/MED1ﬂ/ﬂHCC2 cell lines derived
from these tumors expressed PBP/MED1 prominently in the nucleus
of tumor cells (Figure 7C). We conﬁrmed PBP/MED1 expression in
transplanted HCC by qPCR (Figure 7). PBP/MED1 mRNA level in
tumors was higher than that in the livers of both PBP/MED1ﬂ/ﬂ and
PBP/MED1DLiv mice (Figure 7). Furthermore, we analyzed the
expression of insulin-like growth factor binding protein 1, cyclin D
and cyclin B1 by qPCR (Figure 7). mRNA content of these genes
was signiﬁcantly higher than that seen in PBP/MED1ﬂ/ﬂ and
PBP/MED1DLiv mouse livers which is typical characteristic of tumor
cells.
Fig. 5. DEN induced liver tumors in PBP/MED1ﬂ/ﬂ and PBP/MED1DLiv mice. (A) Liver tumor incidence. Data are mean ± SD. (B) Representative gross
photograph of liver from both groups. (C–F) Histological appearance (hematoxylin and eosin staining; C and E) and immunohistochemical staining for PBP/MED1
(D and F). Liver tumors (T) developing in both PBP/MED1ﬂ/ﬂ and PBP/MED1DLiv mice reveal PBP/MED1 nuclear staining. Non-tumor (NT) areas of PBP/
MED1ﬂ/ﬂ (see boxed in D) but not PBP/MED1DLiv mouse livers (see boxed in F) showed PBP/MED1 nuclear staining of hepatocytes. PBP/MED1 is labeled
as MED1 in panels (A and B).
Fig. 6. HCC metastasized to lungs. Hematoxylin and eosin staining of lung metastases from PBP/MED1 ﬂ/ﬂ (A) and PBP/MED1DLiv (B and C) mice. PBP/MED1
immunostaining of metastatic tumors in the lung of PBP/MED1ﬂ/ﬂ (D) and PBP/MED1DLiv (E and F) mice.
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necrosis in vivo and suppresses colony formation in vitro
The failure of PBP/MED1-deleted hepatocytes to give rise to liver
tumors by PPARa ligand Wy-14,643 (32), or following initiation by
genotoxic carcinogen DEN and promotion by PB as described here,
prompted us to explore the possible biological signiﬁcance of this
coactivator in tumor survival. Since HCC transplanted in nude mice
express PBP/MED1 and the PBP/MED1ﬂ/ﬂ gene in these cells can be
disrupted by adeno-Cre, we injected adeno-Cre-GFP (2   1011 virus
particles) intratumorally in a volume of 100 ll and the tumor har-
vested on the third day for histological analysis (Figure 7C). Exten-
sive areas of tumor necrosis were observed (Figure 7C and D) and the
viable tumor tissue was immunohistochemically positive for PBP/
MED1 (Figure 7D). Deletion of PBP/MED1ﬂ/ﬂ alleles in PBP/
MED1ﬂ/ﬂHCC cell lines by adeno-Cre-GFP resulted in marked sup-
pression of colony formation in soft agar (Figure 7F) as compared
with cells with intact PBP/MED1ﬂ/ﬂ alleles (Figure 7E), further im-
plying the importance of this coactivator in the maintenance of neo-
plastic change. PCR-based genotyping conﬁrmed the deletion of
ﬂoxed PBP/MED1 allele in HCC-1 and HCC-2 cell lines after in-
fection with Ad/Cre-GFP virus resulting into a short band of  1.5
kb after the deletion of ﬂoxed exons 8–10. However, HCC cell lines
infected with Ad/EGFP has intact PBP/MED1 that could not be am-
pliﬁed due to large size of the amplicon ( 5.2 kb) causing PCR
constraint (Figure 7G).
Discussion
In the present study, we show that hepatocyte-speciﬁc deletion of
PBP/MED1ﬂ/ﬂ targeted allelewiththe Alb-Crerecombinase transgene
decreases the susceptibility of PBP/MED1-deﬁcient hepatocytes to
genotoxic carcinogen DEN-induced and PB promoted hepatocarcino-
genesis. In these PBP/MED1DLiv mice, hepatocytes that escaped
Cre-mediated deletion of PBP/MED1ﬂ/ﬂ-targeted allele exhibited pro-
found proliferative potential and these cells are responsible for liver
tumor development in this DEN-initiation and PB promotion liver
tumor model. Accordingly, all liver tumors expressed PBP/MED1
Fig. 7. Liver tumor from PBP/MED1DLiv mouse transplanted in nude mouse. (A) Third generation transplants (in both ﬂanks) are shown. (B) Typical histological
pattern of transplanted tumor expressing PBP/MED1 as assessed by immunohistochemical staining. Panels (C) (hematoxylin and eosin stained) and (D) (PBP/
MED1 immunohistochemical staining) of third generation PBP/MED1ﬂ/ﬂ HCC transplants following intratumoral injection of adeno-Cre-GFP. Areas of necrosis
(N) represent Cre-mediated deletion of the PBP/MED1ﬂ/ﬂ gene. (E and F) Represent soft agar colony formation assay. Treatment of PBP/MED1ﬂ/ﬂHCC cells with
adeno-Cre-GFP caused degeneration and reduction of anchorage-independent colony in soft agar (F) compared with control adeno-EGFP-treated controls (E). (G)
Genotyping of HCC lines (HCC-1 and HCC-2) were done with the primers ﬂanking exon 8–10 of PBP/MED1 allele to conﬁrm the deletion of ﬂoxed DNA.
Infection with Ad/Cre-GFP excised ﬂoxed region which resulted into the ampliﬁcation of mutated band of  1.5 kb whereas infection with Ad/EGFP has an intact
PBP/MED1 genewhich could not be ampliﬁed due to large size of amplicon ( 5.2 kb). Liver genomic DNA from wild-type (C57BL6/J), PBP/MED1ﬂ/ﬂ and PBP/
MED1DLiv mice were used for control. The bar graph panels on the right show the qPCR expression levels of PBP/MED1, insulin-like growth factor binding
protein 1, cyclin D and cyclin B1 in PBP/MED1ﬂ/ﬂ (1), PBP/MED1DLiv (2) mouse livers and liver tumors transplanted in nude mice (3). Standard error bar
represents three independent experiments.
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PBP/MED1-deﬁcient hepatocytes failed to develop liver tumors when
chronically exposed to a non-genotoxic hepatocarcinogen that acts by
enhancing PPARa signaling (27,32). Absence of PBP/MED1 abro-
gates PPARa signaling in hepatocytes and accordingly abolishes the
PPARa-ligand-induced pleiotropic responses including peroxisome
proliferation, induction of fatty acid oxidation enzymes and liver
tumor development (27,32). The data presented here extend these
observations to demonstrate that PBP/MED1-deﬁcient hepatocytes
are also resistant to tumorigenesis initiated by a potent genotoxic
hepatocarcinogen DEN and promoted by PB.
The mechanisms underlying the inability of PBP/MED1-deﬁcient
hepatocytes to give rise to HCC in response to DEN-initiation and PB
promotion can reside at two or more levels. First, the metabolism of
the genotoxic carcinogen DEN, which was used for initiation, could
be defective in hepatocytes with PBP/MED1 deﬁciency as compared
with PBP/MED1ﬂ/ﬂ hepatocytes in the same PBP/MED1DLiv mouse
liver. Metabolic activation of DEN occurs in liver within hours after
administration via cytochrome P450 (CYP)-dependent a-hydroxyl-
ation and oxidation to form reactive products capable of generating
mutagenic DNA adducts (40–42). CYPs involved in DEN metabolism
include CYP1A1, CYP1A2, CYP2B1, CYP2B2 and CYP2E1 and
several of these are regulated by the nuclear receptor CAR (42,43).
In PBP/MED1DLiv mouse liver, the basal mRNA levels of these CYPs
were lower than in PBP/MED1ﬂ/ﬂ livers (30). Parenthetically, it
should be noted that these genes are also not inducible in PBP/
MED1DLiv mouse liver by CAR activators such as PB and the pesti-
cide contaminant 1,4-bis[2-(3,5-dichloropyridyloxy)]benzene (30).
The diminished basal levels of CYPs may account for a reduction
in DEN metabolism and DNA alkylation contributing to lower num-
ber of ‘initiated’ cells among PBP/MED1-deﬁcient cells in compari-
son with PBP/MED1ﬂ/ﬂ hepatocytesin the same liver. Thiscanexplain
the absence of liver tumors with PBP/MED1-deﬁcient genotype in
PBP/MED1DLiv mouse liver. However, given that the mice received
only a single injection of DEN while they were 14 day old, enzyme
induction may not play a major role. Future studies on CYP levels and
DEN-related DNA adducts may provide insights into the role of DEN
metabolism in HCC development in PBP/MED1DLiv mouse liver. Sec-
ond, it has been suggested that the process of initiation, which follows
the primary DNA alkylation reaction, may take several weeks because
two or more rounds of cell division are needed to ﬁx the ‘initiation’
(44). Fixation of critical mutation may not occur in PBP/MED1-
deﬁcient hepatocytes because of their diminished ability to undergo
cell proliferation and this could account for a possible reduction in
the initiated cell population (27,30,32). Third, initiated PBP/MED1-
deﬁcient cells may be highly susceptible to apoptotic cell death
and extinction. We noted a higher incidence of apoptosis in PBP/
MED1-deﬁcient cells and attributed this to compressive pressure on
hepatocytes with inherent defect to divide slowly. Fourth, in this
DEN-initiation–PB promotion liver carcinogenesis model, promotion
of initiated cells is an integral part toward liver tumor development and
evidence suggests that this may be defective in PBP/MED1-deﬁcient
hepatocytes. Promotion of mouse hepatocarcinogenesis by PB involves
the selection of hepatocytes carrying activating mutations and such
a population of initiated cells serves as a sensitive target for PB tumor
promotion. Available evidence indicates that CAR is the molecular
target of promotion by PB and that activation of this nuclear receptor
is an essential requirement for liver tumor development (38).
The DEN-initiation and PB promotion studies in CAR knockout
mice have established that CAR is necessary for liver tumor promo-
tion by PB (39). CAR activation by PB and 1,4-bis[2-(3,5-dichloro-
pyridyloxy)]benzene increases hepatocellular proliferation and
upregulates drug-metabolizing enzymes (39,43). For CAR to exert
its effects on gene expression in liver, PB and other activators of this
receptor have to induce its translocation into hepatocyte nucleus (45).
Of interest is studies using PBP/MED1DLiv mouse livers have clearly
established that PBP/MED1 is essential for the nuclear translocation
of CAR into hepatocytes and for the proper functioning of this xeno-
biotic receptor (30,46,47). In the absence of this coactivator, CAR
remains in the cytoplasm and fails to induce CYP1A2, CYP2B10
and other CAR-regulated genes in liver (30,46). Absence of PBP/
MED1 in liver cells results in the abrogation of hypertrophic and
hyperplastic inﬂuences mediated by CAR ligands (30). DEN is
a genotoxic chemical carcinogen capable of generating DNA ad-
ducts that contribute to mutational events necessary for initiation.
In contrast, carcinogenesis by non-genotoxic mechanisms, for ex-
ample PPARa-and CAR-mediated carcinogenesis, generally in-
volves receptor-mediated cell proliferation and other metabolic
events. The DEN-initiated cells can be inﬂuenced by a variety of
mechanisms that enhance the proliferative capacity of initiated
cells. The studies with PBP/MED1 strongly suggest that this coac-
tivator plays a major role in liver tumorigenesis, whether it is gen-
otoxic and non-genotoxic carcinogenesis.
Finally, we have established a transplantable HCC in athymic nude
mice that expresses high levels of insulin-like growth factor binding
protein 1, cyclin D and cyclin B1 and show that deletion of PBP/
MED1ﬂ/ﬂ allele using adeno-Cre results in tumor cell necrosis. Two
HCC cell lines with PBP/MED1ﬂ/ﬂ allele have also been generated and
preliminary studies suggest that adeno-Cre-mediated disruption of
PBP/MED1 gene in these cells inhibits colony formation in soft agar
and tumor formation in nude mice. We have previously reported that
PBP/MED1(PPARBP) gene, which islocalized tochromosome17q12,
a region known to contain the oncogene erbB-2/HER-2, is ampliﬁed
and overexpressed in breast cancer (48). Recently, it has been shown
that the loss of this coactivator inhibits prostate cancer cell proliferation
and survival (49). The available data indicate that PBP/MED1 is im-
portant for cell proliferation and neoplastic growth and the absence of
this molecule adversely affects cell growth. In contrast, a recent study
shows that downregulation of the expression of this coactivator in fact
enhances the tumorigenic phenotype of human melanoma cells (50). It
is possible that PBP/MED1 may exert different effects in different
tumor cell types. Additional studies are needed to understand the func-
tion of PBP/MED1 and other essential coactivators such as PRIP (51)
in tumor formation, growth and survival in liver and other types of
cancers.
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